PLSE Stock Analysis: Pulse Biosciences | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 3.393m USD | 12M Return: 248.6% | US74587B1017 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 19.1M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pulse Biosciences, Inc. (PLSE) is a U.S.-based bioelectric medicine company headquartered in Miami, Florida, founded in 2014 (formerly Electroblate, Inc., renamed in December 2015). The company develops the nPulse platform, which is built around Nanosecond Pulsed-Field Ablation (nsPFA) technology. Its product line spans dermatology, soft tissue ablation, and cardiac applications, including systems designed for treating atrial fibrillation and skin lesions, along with a console-based software platform to support physician workflows.
The company operates in the medical device sector, specifically within healthcare equipment, where pulsed-field ablation represents an emerging energy modality being investigated as an alternative to traditional thermal ablation methods (such as radiofrequency or cryoablation) for cardiac arrhythmias. Pulse Biosciences is classified as a small-cap stock, indicating a relatively modest market capitalization compared to larger medical device peers.
- FDA approval timeline for cardiac catheter system drives valuation
- Boston Scientific FARAPULSE competition intensifies in pulsed-field ablation market
- Cash burn and dilution risk from ongoing equity capital raises
| Net Income: -80.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.53 > 0.02 and ΔFCF/TA -15.92 > 1.0 |
| NWC/Revenue: 7.99k% < 20% (prev 3.97k%; Δ 4.02k% < -1%) |
| CFO/TA -0.53 > 3% & CFO -61.1m > Net Income -80.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (69.2m) vs 12m ago 2.86% < -2% |
| Gross Margin: -21.60% > 18% (prev 33.93%; Δ -55.54% > 0.5%) |
| Asset Turnover: 1.01% > 50% (prev 2.08%; Δ -1.07% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.82 (Total Current Assets 105.7m - Total Current Liabilities 11.0m) / Total Assets 115.6m |
| B: -4.38 (Retained Earnings -506.5m / Total Assets 115.6m) |
| C: -0.70 (EBIT TTM -83.0m / Avg Total Assets 117.9m) |
| D: 6.19 (Book Value of Equity 99.5m / Total Liabilities 16.1m) |
| Altman-Z'' = -7.14 = D |
| DSRI: 3.0 (Receivables 122k/15.0k, Revenue 1.19m/2.50m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.81 (AQ_t 0.03 / AQ_t-1 0.04) |
| SGI: 0.47 (Revenue 1.19m / 2.50m) |
| TATA: -0.16 (NI -80.1m - CFO -61.1m) / TA 115.6m) |
| Beneish M = -1.89 (Cap -4..+1) = B |
As of September 03, 2026, the stock is trading at USD 52.68 with a total of 977,760 shares traded. Over the past week, the price has changed by +9.52%, over one month by +39.62%, over three months by +116.97% and over the past year by +248.64%.
Current recommended Stop Loss: 49.30 (which is 6.4% or 1.1 ATR below the current price).
Pulse Biosciences has no consensus analysts rating.
| Analysts Target Price | 45.3 | -14.1% |
P/S = 2863.1362
P/B = 34.8513
Revenue TTM = 1.19m USD
EBIT TTM = -83.0m USD
EBITDA TTM = -82.0m USD
Long Term Debt = 5.09m USD (estimated: total debt 6.77m - short term 1.69m)
Short Term Debt = 1.69m USD (from shortTermDebt, last quarter)
Debt = 6.77m USD (from shortLongTermDebtTotal, last quarter) (leases 6.77m already included)
Net Debt = -94.8m USD (calculated: Debt 6.77m - CCE 101.6m)
Enterprise Value = 3.30b USD (3.39b + Debt 6.77m - CCE 101.6m)
Interest Coverage Ratio = unknown (Ebit TTM -83.0m / Interest Expense TTM 0.0)
EV/FCF = -53.72x (Enterprise Value 3.30b / FCF TTM -61.4m)
FCF Yield = -1.86% (FCF TTM -61.4m / Enterprise Value 3.30b)
FCF Margin = -5.18k% (FCF TTM -61.4m / Revenue TTM 1.19m)
Net Margin = -6.76k% (Net Income TTM -80.1m / Revenue TTM 1.19m)
Gross Margin = -21.60% ((Revenue TTM 1.19m - Cost of Revenue TTM 1.44m) / Revenue TTM)
Gross Margin QoQ = 37.10% (prev 7.73%)
Tobins Q-Ratio = 28.54 (Enterprise Value 3.30b / Total Assets 115.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 6.77m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -65.6m (EBIT -83.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.63 (Total Current Assets 105.7m / Total Current Liabilities 11.0m)
Debt / Equity = 0.07 (Debt 6.77m / totalStockholderEquity, last quarter 99.5m)
Debt / EBITDA = 1.16 (negative EBITDA) (Net Debt -94.8m / EBITDA -82.0m)
Debt / FCF = 1.55 (negative FCF - burning cash) (Net Debt -94.8m / FCF TTM -61.4m)
Total Stockholder Equity = 84.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -67.90% (Net Income -80.1m / Total Assets 115.6m)
RoE = -94.42% (Net Income TTM -80.1m / Total Stockholder Equity 84.8m)
RoCE = -92.40% (EBIT -83.0m / Capital Employed (Equity 84.8m + L.T.Debt 5.09m))
RoIC = -61.77% (negative operating profit) (NOPAT -65.6m / Invested Capital 106.2m)
WACC = 7.64% (E(3.39b)/V(3.40b) * Re(7.66%) + D(6.77m)/V(3.40b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 7.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 90.46 | Cagr: 10.59%
[DCF] Fair Price = unknown (Cash Flow -61.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.34 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: -0.53 | # QB: 0
EPS current Quarter (2026-09-30): EPS=-0.29 | Chg30d=-3.51% | Revisions=-25% | Analysts=2
EPS current Year (2026-12-31): EPS=-1.10 | Chg30d=-3.27% | Revisions=+25% | GrowthEPS=-46.5% | GrowthRev=+461.9%
EPS next Year (2027-12-31): EPS=-1.16 | Chg30d=-5.96% | Revisions=+25% | GrowthEPS=-4.5% | GrowthRev=+301.7%
[Analyst] Revisions Ratio: +17% (up=2, down=1)